This is compared to 83% ... Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough Designation July 10, 2024 — CAR-T cell therapy helps some with intractable lymphoma ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

Adult patients with R/R DLBCL with eligible subtypes, including transformed DLBCL, were enrolled. Patients must have received ≥2 previous lines of systemic therapy, be ineligible for hematopoietic SCT ...

which launches its CAR-T cell therapy to treat adult patients with lymphoma on Monday, is focused on making it affordable for cancer patients in India, having brought down costs to about 10% of ...

Blander and her colleagues chose to study a mouse model of B-cell lymphoma called Eµ-myc, which has a mutation in the Myc oncogene. These mice have a long delay before tumors develop, giving ...

Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) occurs when lymphocytes called T cells and B cells become ...

The American Cancer Society’s most recent estimates for all types of non-Hodgkin lymphoma (NHL) in the United States for 2025 are: 80,350 new cases of NHL (45,140 in men and 35,210 in women) 19,390 ...

The investigators tested these CAR-NK cells alone in 18 patients and for the remainder in combination with rituximab, a monoclonal antibody that helps further target the CAR-NK cells to lymphoma ...

Loncastuximab tesirine is a CD19-directed antibody and alkylating agent currently FDA-approved to treat refractory or relapsed large B-cell lymphoma in adults ... trials in the treatment of high-risk ...